2-bromo-1-methoxy-4-propylbenzene | 101538-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-1-methoxy-4-propylbenzene
• CAS: 101538-30-1
• 化学式: C₁₀H₁₃BrO
• 分子量: 229.117
• InChiKey: PNMJTQBMYMRTAF-UHFFFAOYSA-N

物化性质

• 沸点：
  266.8±20.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-1-methoxy-4-propylbenzene 在 四氧化锇 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 水 、 氯化二乙基铝 、 sodium carbonate 、 potassium carbonate 、 对甲苯磺酸 、 N-甲基吗啉氧化物 作用下， 以 甲醇 、 乙二醇二甲醚 、 正己烷 、 水 、 丙酮 、 叔丁醇 为溶剂， 反应 49.0h， 生成 3-(4,2'-dimethoxy-5'-propyl-biphenyl-3-yl)-propane-1,2-diol
  参考文献：
  名称：

  METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE

  摘要：

  本发明公开了一种生产厚朴酚及其类似物的方法，以及由此制备的新颖中间体。还公开了一种用于治疗帕金森病的药物组合物，该组合物包含厚朴酚和/或其类似物。

  公开号：

  US20130303788A1
• 作为产物：
  描述：

  4-丙基苯酚 在 溴 、 苄基三丁基溴化铵 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 12.0h， 生成 2-bromo-1-methoxy-4-propylbenzene
  参考文献：
  名称：

  Structural analogues of the natural products magnolol and honokiol as potent allosteric potentiators of GABAA receptors

  摘要：

  Biphenylic compounds related to the natural products magnolol and 4'-O-methylhonokiol were synthesized, evaluated and optimized as positive allosteric modulators (PAMs) of GABA(A) receptors. The most efficacious compounds were the magnolol analog 5-ethyl-5'-hexylbiphenyl-2,2'-diol (45) and the honokiol analogs 4'-methoxy-5-propylbiphenyl-2-ol (61), 5-butyl-4'-methoxybiphenyl-2-ol (62) and 5-hexyl-4'- methoxybiphenyl-2-ol (64), which showed a most powerful potentiation of GABA-induced currents (up to 20-fold at a GABA concentration of 3 mu M). They were found not to interfere with the allosteric sites occupied by known allosteric modulators, such as benzodiazepines and N-arachidonoylglycerol. These new PAMs will be useful as pharmacological tools and may have therapeutic potential for mono-therapy, or in combination, for example, with GABA(A) receptor agonists. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.10.027

文献信息

• Reagents and synthetic methods—40
  作者：J.M. Aizpurua、M. Juaristi、B. Lecea、C. Palomo

  DOI：10.1016/s0040-4020(01)96614-1

  日期：1985.1

  efficient for the oxidation of alcohols to carbonyl compounds, for the oxidative coupling of mercaptans into disulfides and for a mild cleavage of oximes to carbonyl compounds. Chlorotrimethylsilane-chromium trioxide has been shown to be an efficient oxidizing agent for the conversion of arylmethanes to benzaldehydes. The reagent is applied to the oxidative cleavage of some benzyl esters. A mild procedure

  描述了卤代硅烷-三氧化铬试剂作为优异的新型氧化剂的合成用途。它们对于将醇氧化为羰基化合物，将硫醇氧化偶联为二硫化物以及将肟温和裂解为羰基化合物非常有效。氯三甲基硅烷-三氧化铬已被证明是将芳基甲烷转化为苯甲醛的有效氧化剂。该试剂用于某些苄基酯的氧化裂解。还描述了通过该试剂和分子碘原位产生的碘鎓物质进行有机化合物碘化的温和程序。
• METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE
  申请人：Chan Ming-Huan

  公开号：US20130303788A1

  公开（公告）日：2013-11-14

  A method of producing honokiol and analogues thereof, and novel intermediates prepared by virtue thereof are disclosed herein. A pharmaceutical composition for treating Parkinson's disease, which contains honokiol and/or the analogues thereof, is also disclosed herein.

  本发明公开了一种生产厚朴酚及其类似物的方法，以及由此制备的新颖中间体。还公开了一种用于治疗帕金森病的药物组合物，该组合物包含厚朴酚和/或其类似物。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070099874A1

  公开（公告）日：2007-05-03

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及用于治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖化蛋白诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗由平滑肌增殖所特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。
• Quantitative structure-activity analysis of larvicidal 1-(substituted benzoyl)-2-benzoyl-1-tert-butylhydrazines against<i>Chilo suppressalis</i>
  作者：Nobuhiro Oikawa、Yoshiaki Nakagawa、Keiichiro Nishimura、Tamio Ueno、Toshio Fujita

  DOI：10.1002/ps.2780410210

  日期：1994.6

  AbstractThe larvicidal activity of a number of 1‐(substituted benzoyl)‐2‐benzoyl–1 ‐ten‐butylhydrazines against the rice stem borer (Chilo suppressalis Walk.) was measured. Variations in the activity were examined quantitatively using physico‐chemical substituent and molecular parameters and regression analysis. The results indicated that the molecular hydrophobicity and the electron‐withdrawing inductive/ field effect of ontho substituents are favourable to larvicidal activity. The bulkiness of substituents at the meta and para positions was unfavourable to activity, substitution at the para position being more unfavourable than that at the meta position in terms of van der Waals' volume. The 2,3–, 2,5‐ and 2,6‐disubstitution patterns were also unfavourable to activity. Reductions in larvicidal activity caused by the 2,6‐,‐ 2,3,5‐ and 2,3,4,5‐substitutions were greater than those induced by the 2,3‐ and 2,5‐disubstitutions. When the sum of contributions from favourable effects is greater than that from unfavourable effects, the larvicidal activity is expected to be superior to that of the unsubstituted compound.